Literature DB >> 22895149

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Nir Peled1, Gary Palmer, Fred R Hirsch, Murry W Wynes, Maya Ilouze, Marileila Varella-Garcia, Lior Soussan-Gutman, Geoff A Otto, Philip J Stephens, Jeffrey S Ross, Maureen T Cronin, Doron Lipson, Vincent A Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22895149      PMCID： PMC3645938          DOI： 10.1097/JTO.0b013e3182614ab5

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

3.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582
  3 in total
  45 in total

1.  Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Authors:  D Ross Camidge; Margaret Skokan; Porntip Kiatsimkul; Barbara Helfrich; Xian Lu; Anna E Barón; Nathan Schulte; DeLee Maxson; Dara L Aisner; Wilbur A Franklin; Robert C Doebele; Marileila Varella-Garcia
Journal:  Cancer       Date:  2013-09-10       Impact factor: 6.860

Review 2.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

3.  Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Authors:  Marina Pekar-Zlotin; Fred R Hirsch; Lior Soussan-Gutman; Maya Ilouze; Addie Dvir; Theresa Boyle; Murry Wynes; Vincent A Miller; Doron Lipson; Gary A Palmer; Siraj M Ali; Shlomi Dekel; Ronen Brenner; Paul A Bunn; Nir Peled
Journal:  Oncologist       Date:  2015-02-26

Review 4.  Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.

Authors:  Xiaomin Niu; Jody C Chuang; Gerald J Berry; Heather A Wakelee
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

5.  [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

Authors:  M von Laffert; P Schirmacher; A Warth; W Weichert; R Büttner; R M Huber; J Wolf; F Griesinger; M Dietel; C Grohé
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

6.  ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.

Authors:  Andrew S Williams; Wenda Greer; Drew Bethune; Kenneth J Craddock; Gordon Flowerdew; Zhaolin Xu
Journal:  Virchows Arch       Date:  2016-08-25       Impact factor: 4.064

Review 7.  Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.

Authors:  Alex Friedlaender; Giuseppe Banna; Sandip Patel; Alfredo Addeo
Journal:  Curr Treat Options Oncol       Date:  2019-09-04

8.  Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.

Authors:  Francesco Gelsomino; Giulio Rossi; Marcello Tiseo
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

9.  Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.

Authors:  Jin Sung Jang; Xiaoke Wang; Peter T Vedell; Ji Wen; Jinghui Zhang; David W Ellison; Jared M Evans; Sarah H Johnson; Ping Yang; William R Sukov; Andre M Oliveira; George Vasmatzis; Zhifu Sun; Jin Jen; Eunhee S Yi
Journal:  J Thorac Oncol       Date:  2016-06-22       Impact factor: 15.609

Review 10.  Prognostic and predictive biomarkers in lung cancer. A review.

Authors:  Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.